Amgen Inc. (NASDAQ: AMGN)

Sector: Medical

Current Price : $104.24

52 Week Low
$67.1352 Week High
$111.57

Press Releases
Amgen To Present At The UBS Global Life Sciences Conference
New Analyses Identify Predictive Biomarkers For Vectibix? (Panitumumab) In Patients With Metastatic Colorectal Cancer
Amgen Highlights Data To Be Presented At American Society of Clinical Oncology Annual Meeting
Strategy Behind Our Success, We Get in Early: PSX, AMGN, MPC and BAX
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Free Research Reports on AMGN, OPK, SLAB and VOCS Issued by the Bedford Report
The Reason It Trades, What's Moving PLD, AKAM, GE and AMGN
Amgen's First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
Amgen Announces Webcast of 2013 First Quarter Financial Results
Perfect Trade Setups, How to Play AMGN, GILD, JCP and PCLN
The Real Story Behind AMGN, NWSA, VLO and AXP
Pharmaceutical Companies, Investor Coalition Develop Industry Standard-Setting Principles for Recoupment Policies Covering Major Compliance Failures
Morning Research on Amgen, Affymax, Vertex Pharma, Questcor Pharma, and Repros Therapeutics
Key to Success, How to Profit: LULU, VZ, EMC and AMGN
The Real Story Behind BIDU, YHOO, AIG and AMGN
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
Did You Miss DTV, AMGN, PM and F
Special Situation Coming Soon, a Look Inside CELG, CVX, AMGN and EBAY
A Forward Look, the Year Ahead - Research Report on Amgen, Inc., Bristol Myers Squibb Co., Ann Inc., Limited Brands, Inc. and AMETEK, Inc.
Special Offer for Shareholders of GOOG, AMGN, PBR and GILD
Amgen Announces 2013 Second Quarter Dividend
Key to Success, How to Profit: AMZN, AMGN and BIDU
Next Week's Trade Setups, What's in Store for WRC, AMGN, HLF and MNST
Amgen To Present At The Cowen and Company 33rd Annual Health Care Conference
The Real Story Behind MON, FTE, RRC and AMGN
A New Direction, What's Ahead - Research Report on Newmont Mining Corp, AMETEK, Inc., Honeywell International Inc., Amgen, Inc. and Bristol Myers Squibb Co.
Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
Market Movers, Money Makers -- Start Now With NFLX, WMT, AMGN and APA
Making All the Right Moves in FB, WFC, MDLZ and AMGN
Turn Timing Into Profits With HNZ, CMCSA, AIG and AMGN
Amgen Announces Call For Nominations For 2013 Breakaway From Cancer? Champions
Did You Miss NOV, AMGN, BIDU and CVX
Amgen Outlines Long-Term Strategy
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
U.S. Food and Drug Administration Approved 30% More Drugs in 2012
Amgen Inc. [AMGN] to Ring The NASDAQ Stock Market Opening Bell
Amgen To Webcast 2013 Business Review Meeting On February 7
Free Research Report on Marriott Vacations Worldwide Corp, Copart, Inc., Five Below, Inc., City National Corp. and Amgen Inc.
Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
Amgen Announces Results From Phase 3 PAVES Study Evaluating Neulasta? (pegfilgrastim) In Patients With Colorectal Cancer
Amgen Backs States' Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
Amgen's Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
Pill Economics - Research Report on Arena Pharmaceuticals, Inc. and Amgen, Inc.
Amgen Announces Webcast of 2012 Fourth Quarter and Full Year Financial Results
Amgen Announces Top-Line Results Of Phase 3 Aranesp? (darbepoetin alfa) RED-HF? Trial
Amgen To Present At The 31st Annual J.P. Morgan Global Healthcare Conference
Amgen Finalizes Agreement Resolving Previously Announced Federal Investigations
Amgen Announces Appointment of Robert A. Eckert to Board of Directors
Amgen Names Robert A. Bradway Chairman of the Board Of Directors
Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
Amgen Highlights Data To Be Presented At American Society of Hematology Annual Meeting
Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting
The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia
Journal of the American Medical Association Publishes AMG 145 Phase 2 GAUSS Study Showing Significant Reductions In LDL Cholesterol In Statin-Intolerant Patients
Phase 3 Sensipar?/Mimpara? EVOLVE(tm) Trial Published In The New England Journal Of Medicine
Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
Amgen To Webcast Investor Meeting At Upcoming American Heart Association Scientific Sessions 2012
Traders Look to New Levels Ahead - Research & Analysis on Amgen Inc. and Glaxosmithkline Plc
Amgen Announces Webcast of 2012 Third Quarter Financial Results
Amgen Presents Several Sub-Analyses At ASBMR From The Ongoing Open-Label Extension Study Of The Pivotal Phase 3 Prolia Fracture Trial
Amgen Appoints Cynthia Patton Senior Vice President And Chief Compliance Officer
Amgen Announces 2012 Fourth Quarter Dividend
FDA Approves New Indication For Prolia? (Denosumab) For The Treatment Of Bone Loss In Men With Osteoporosis At High Risk For Fracture
Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference
Market Influences That Drive Equities Forward - Industry Report on Gilead Sciences, Inc. and Amgen Inc.
Amgen To Present At The Morgan Stanley Global Healthcare Conference
A Refreshing Outlook - Consensus Reports on Gilead Sciences, Inc. and Amgen Inc.
Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
Amgen and Idenix Pharmaceuticals Showing Strong Growth -- Biotech Industry Booming in 2012
Amgen Announces Webcast of 2012 Second Quarter Financial Results
Amgen Announces 2012 Third Quarter Dividend
Amgen Completes Acquisition of KAI Pharmaceuticals
Biotech Companies -- Led by Amgen and Celgene -- Increase R&D Spending in 2011
Actress Maura Tierney And Amgen Launch The Chemotherapy: Myths or Facts(tm) Campaign
Where Opportunity Is Found - Research & Analysis on Abbott Laboratories and Amgen, Inc.
Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
20th Annual Amgen Award For Science Teaching Excellence Honors Nine Outstanding Teachers
Amgen Announces Top-Line Results Of Phase 3 Sensipar?/Mimpara? EVOLVE(tm) Trial
Amgen Announces Voting Results of Annual Meeting of Stockholders
Amgen's BiTE? Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Analysis Of Rilotumumab (AMG 102) Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer
Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
Amgen to Present at the Baird Growth Stock Conference
Equity Research on Spectrum Pharmaceuticals Inc. and Amgen Inc. - Biotechnology Companies Releasing Strong Earnings
Amgen to Present at the Deutsche Bank 37th Annual Healthcare Conference
Four Californians Selected As Breakaway from Cancer? Champions To Be Honored During Amgen Tour of California
Amgen Receives Complete Response Letter From FDA for XGEVA? sBLA for Prevention of Bone Metastases
Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61
A Tribute to George Rathmann, Amgen's Founding CEO (1927-2012)
Amgen Announces Webcast of 2012 First Quarter Financial Results
Amgen to Acquire Privately Held KAI Pharmaceuticals
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
Amgen and AstraZeneca Announce Collaboration to Jointly Develop and Commercialize Clinical-Stage Inflammation Portfolio
Amgen Announces Phase 2 Study Results for Brodalumab in Moderate to Severe Plaque Psoriasis Published in the New England Journal of Medicine
Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol up to 81 Percent in Phase 1b Study

iStock Rating

Amgen Inc. (NASDAQ: AMGN)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios